analysis of pk data- pop pk analysis

26
Analysis of population PK Data Gayatri Devi R Student 5 th PHARM D

Upload: gayathri-ravichandran

Post on 13-Dec-2014

210 views

Category:

Education


2 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Analysis of pk data- Pop PK analysis

Analysis of population PK Data

Gayatri Devi R

Student 5th PHARM D

Page 2: Analysis of pk data- Pop PK analysis

PHARMACOKINETIC DATA intended to define the time course of drug

and major metabolite concentrations in plasma and other biological fluids in order to obtain information on absorption, distribution, metabolism, and elimination.

Importance?? Pharmacokinetically guided dose escalation

(PGDE) studies Dose fixing in Phase II and subsequent studies. To adapt drug dosage to the individual patient

(therapeutic drug monitoring)

Page 3: Analysis of pk data- Pop PK analysis

Relevant PK parameters Total clearance (CL), Fraction of dose excreted unchanged in urine

(fe), Volume of distribution at steady state (Vss), Volume of distribution during the terminal

phase (VZ), Blood/plasma concentration ratio, Terminal half-life (t1/2 Z), Fraction of unbound drug in plasma (fu), Bioavailable fraction of dose (F), if applicable,

and Absorption rate constant (ka),

Page 4: Analysis of pk data- Pop PK analysis

Designing a dosage regimen..Following parameters should be known as well: Area under the plasma concentration time

curve(AUC), Maximum concentration (Cmax), Minimum concentration (Cmin) after repeated

dosing, and Time of Cmax (tmax). In addition, the effective and toxic

concentrations should be assessed

Page 5: Analysis of pk data- Pop PK analysis

Population PK: from 1972 to 1977 Population pharmacokinetics is the study of

the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest.

Pop PK seeks to identify the measurable pathophysiologic factors that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically significant shifts in the therapeutic index, dosage can be appropriately modified.

Page 6: Analysis of pk data- Pop PK analysis

Population pharmacokinetics incl: Assessment of global variability of the plasma

drug concentration profile in a patient population. Allocation of this variability to pharmacokinetic

parameters (e.g. variability of clearance, bioavailability, etc).

Explanation of variability by identifying factors of demographic, pathophysiological, environmental, or concomitant drug-related origin that may influence the pharmacokinetic parameters.

Quantitative estimation of the magnitude of the unexplained variability in the patient population.

Page 7: Analysis of pk data- Pop PK analysis

What does PK software do? Fitting drug concentration-versus-time data to

a series of pharmacokinetic models, and choosing the one that best describes the data statistically.

Fitting data into a pharmacokinetic or pharmacodynamic model defined by the user

Simulation Experimental design Clinical pharmacokinetic applications Computer programs for teaching

Page 8: Analysis of pk data- Pop PK analysis

The application of population analysis methods to therapeutic problems has led to on-going methodological and software development which in further has established more complex applications.

Commonly used softwares used for analysis of PK data: NONEM (NONlinear Mixed Effects Modeling) * -

developed by S.L.Beal and L.B. Sheiner MK MODEL – developed by National Institutes Of

Health Support PROPHET system NPEM 2 ( Non Parametric Expectation

Maximization), version 3- well adapted for Pop Pk

Page 9: Analysis of pk data- Pop PK analysis
Page 10: Analysis of pk data- Pop PK analysis

Model setup screen of NLME

Page 11: Analysis of pk data- Pop PK analysis

Other softwares incl. USCPACK PC PROGRAMS*

Consists of various Pk programs Clinical programs incl. related routines in which

past therapy data for individual patients are entered into files along with parameter and dose predication programs for various drugs like:

Amikacin(amik) Gentamicin(Gent) Netilmicin(Net) Tobramycin (Tob) Bayesian General Modeling (MB) Least Squared General Modeling

Page 12: Analysis of pk data- Pop PK analysis

Population analysis Synonym: repeated measures modeling, non

linear mixed effects modeling, non linear hierarchical modeling.

Pop PK analysis refer to a set of statistical techniques that can be used to learn about the average response in a population as well as the variability in response that arises from different sources.

Population analysis is the application of a model to describe data that arise from more than one individual

Page 13: Analysis of pk data- Pop PK analysis

Approaches for analyzing Pop PK data Standard two - stage approach

refers to fitting a pharmacokinetic model to the data of each individual

Afterwards summary statistics are computed for the total collection of individual parameter estimates

Using this approach, the inter individual variance tends to be overestimated.

it is not applicable when the individual data are too sparse for individual model fits.

Page 14: Analysis of pk data- Pop PK analysis

Contd.. Nonlinear Mixed-Effects Modelling Approach

With this type of modelling not only pharmacokinetic parameters but also inter-individual variance parameters are estimated.

The parameters are population means, shift parameters, and inter-individual and residual variance parameters

A population pharmacokinetic data analysis should include relevant covariates, e.g. age, weight, gender, creatinine clearance, co-medication, and concomitant diseases

Quantitative relationships between covariates and pharmacokinetic parameters often help predict individual PK before any individual data have been obtained.

Page 15: Analysis of pk data- Pop PK analysis

Considering an example…. PK model for a gentamicin-like drug that incorporates

the central elements relevant to a population analysis.

This drug displays one compartment model characteristics

Vd =20 L and clearance (4 L Hr -1) dose admn by IV bolus.

We used this PK model to simulate plasma concentration–time data for 30 patients who received a single intravenous bolus dose of 420 mg (6 mg /kg for a 70 kg individual),where each patient provided seven blood samples at times 0.25, 0.5, 1, 2, 4, 8 and 12 h following dosing.

Page 16: Analysis of pk data- Pop PK analysis

Observed conc-time data for 30 samples

Page 17: Analysis of pk data- Pop PK analysis

A population analysis was then conducted on the simulation 'dataset’.

A population model for our data will consist of three elements:

(1) A model for the typical response – this is the response for a typical (average) patient, (2) a model for heterogeneity and (3) a model for uncertainty.

Page 18: Analysis of pk data- Pop PK analysis

Model for typical response This is sometimes also called a structural

model. For pharmacokinetics this would be a compartmental model that describes the plasma drug concentration over time (see Figure 2A).

The pharmacokinetic model that describes our gentamicin- like drug at a specific time (t) is:

Page 19: Analysis of pk data- Pop PK analysis

A) The observed concentration–time data overlaid with the median predictedconcentration from the PK model. (B) Observed concentration–time data overlaid with the median and 2.5th and 97.5th percentiles of the predicted concentrations from the PK model

Page 20: Analysis of pk data- Pop PK analysis

Model of heterogeneity We use the term heterogeneity in population

analysis to describe the variability between individuals. This is also termed Between Subject Variability (BSV) or Inter-Individual Variability (IIV).

This involves two distinct models: a model developed to describe predictable

reasons why individuals are different. a model developed to quantify the remaining

source of random variability Figure 2B encompass the observed plasma

concentration data of our PK example.

Page 21: Analysis of pk data- Pop PK analysis

CLCR as an abbreviation for creatinine clearance CLNR as an abbreviation for non-renal clearance

EXPLANATION:

Page 22: Analysis of pk data- Pop PK analysis

FIGURE 3Individual estimates of systemic drug CL vs. creatinine clearance.

The line is the regression line and the intercept represents non-renal clearanceand the slope represents the fraction of drug cleared unchanged by the kidneys. The vertical difference of any individual from the regression line represents the difference of that individual from the population average and is given by c (Equation3)

Page 23: Analysis of pk data- Pop PK analysis

Predicted concentrations from the PK model that does not include the covariate CLCR (solid line). Predicted concentrations from a PK model that includes the covariate CLCR as a covariate on CL (dashed lines).

Includingthe covariate CLCR in the model reduces the unexplained variability in the model predictions and hence improves the reliability of the model predictions

Page 24: Analysis of pk data- Pop PK analysis

Model for Uncertainty This model describes why the 1st and 2nd models do

not match the observations exactly. Uncertainty is also called residual error. It is

assumed that uncertainty arises from (at least) four sources: (i) process error – where the dose or timing of dose or timing of blood samples are not conducted at the times that they are recorded, (ii) measurement error – where the response (e.g. concentration) is not measured exactly due to assay error, (iii) model misspecification – where the models we propose in Equations 1–3 are in reality too simple and (iv) moment to moment variability within a patient.

Page 25: Analysis of pk data- Pop PK analysis

The final component to add to our analysis must account for the uncertainty in our model predictions. We need to assume (not essential but) that the uncertainty is entirely random and due to error; so by incorporating,

This error represents the (residual) difference of themodel prediction from the data

Page 26: Analysis of pk data- Pop PK analysis

Why Pop PK are performed???